UCSF
San Francisco, California, 94158, United States
Location status: Recruiting
NCT Number: NCT06898788
This double-blind, placebo-controlled clinical trial will examine the effect of probiotic Visbiome on the brain and gut microbiome of individuals 15 to 24 years of age.
Interested in participating?
Request Info15 year–24 year
All sexes
Interventional
Early Phase 1
San Francisco, California, 94158, United States
Location status: Recruiting
This trial will evaluate the effects of Visbiome 450 billion CFU taken orally twice daily on the biological signature of left hippocampal (HP) resting-state functional connectivity (RSFC) and gut microbiome composition in individuals between the ages of 15 and 24 years.This study will assess the safety and tolerability of Visbiome at this dosage.
Participants will be enrolled in the study for a total of eight weeks and randomized to the probiotic or placebo group. Follow-up assessments will take place every two weeks and will be conducted either through Zoom video visits or in person. The primary outcomes of the study include the effects of the intervention on neural connectivity and gut microbiome composition. Neural connectivity will be assessed by measuring the left HP RSFC using functional magnetic resonance imaging (fMRI). Gut microbiome composition will be evaluated by assessing beta diversity through stool samples collected at baseline and post-intervention.
The safety and tolerability of the intervention will be carefully monitored throughout the study. Adverse events will be systematically collected at each visit, graded for severity, and evaluated for their relationship to the probiotic intervention. Tolerability will be assessed using the Generic Assessment of Side Effects - Probiotics (GASE-P). This measure will be administered at baseline and every two weeks throughout the study period.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Visbiome® is an oral multi-strain probiotic which contains 8 strains: Lactobacillus (L.) paracasei, L. planatrum, L. acidophilus, L. helveticus, Bifidobacterium (B.) longum, B. infantis, B. breve, and Streptococcus (S.) thermophilus.
Participants will be instructed to consume the powder mixed in water.
Participants will be instructed to consume the powder mixed in water (same instructions as the probiotic group).
Time frame: Baseline and week 8
Measured with fMRI.
Time frame: Baseline and week 8
Gut microbiome measurement
Time frame: Every 2 weeks from baseline to week 8
Assesses for tolerability, safety, and adverse events.
Contact information is provided by the study sponsor or research team.
University of California, San Francisco
Other
Acronym: PAD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07654179
Behavior, Behavioral Symptoms
Rawalpindi, Punjab Province, Pakistan
View Trial DetailsNCT06511908
Behavior, Behavioral Symptoms
Bethesda, Maryland, United States
View Trial DetailsNCT07512284
Behavior, Behavioral Symptoms
San Diego, California, United States
View Trial DetailsNCT05282277
Anhedonia, Behavior
Chapel Hill, North Carolina, United States
View Trial Details